Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2021-05-20 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第三届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 18th meeting of the 3rd Board of Directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and the voting results on a specific agenda item related to the cancellation of unexercised stock options. The content focuses on board meeting decisions and procedural compliance, without presenting financial statements or detailed financial performance data. It is not an annual report, earnings release, or any financial report. It is not a proxy solicitation or voting results announcement for a shareholder meeting but rather a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and specific to board decisions, confirming this classification with high confidence.
2021-05-20 Chinese
关于注销公司2018年（第一期）股票期权激励计划第二个行权期满未行权期权的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of unexercised stock options under its 2018 stock option incentive plan. It details board and supervisory committee approvals, independent director opinions, legal opinions, and the impact on the company. The document is relatively short (4194 characters) and focuses on a specific corporate action related to stock options, not a full financial report or earnings release. It is not a report itself but an announcement of a corporate governance action related to stock option cancellations. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about stock option cancellations and related approvals, not a full management report, audit report, or capital update. Therefore, the classification is RNS with high confidence.
2021-05-20 Chinese
独立董事关于第三届董事会第十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding a specific board meeting resolution about the cancellation of unexercised stock options under a stock option incentive plan. It references regulatory guidelines and company internal rules but does not contain financial statements or detailed financial data. The document is short (851 characters) and focuses on board/management matters related to stock option plan administration. It is not an annual report, audit report, earnings release, or any financial report. It is also not a voting result announcement or a proxy solicitation. The content fits best under Board/Management Information (MANG) as it relates to board decisions and management oversight on stock option cancellations.
2021-05-20 Chinese
第三届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a meeting resolution announcement from the supervisory board of a company regarding the cancellation of unexercised stock options under a stock option incentive plan. It includes details about the meeting date, attendance, agenda, and voting results. The document does not contain financial statements or detailed financial analysis, nor is it a full report like an annual or interim report. It is not a call transcript, earnings release, or capital update. It is a formal announcement of a board/supervisory meeting decision related to corporate governance and stock option management. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a specific board decision, not a report publication or regulatory filing. Hence, the classification is MANG with high confidence.
2021-05-20 Chinese
股东股份减持的进展公告
Transaction in Own Shares Classification · 95% confidence The document is a shareholder announcement regarding the progress of a shareholding reduction by a specific shareholder (温州特瑞西创企业管理合伙企业). It details the number of shares reduced, the methods of reduction (centralized bidding and block trades), dates, prices, and the shareholder's holdings before and after the reduction. It also references compliance with relevant regulations on shareholding reduction by shareholders and senior management. There is no financial statement, earnings data, or management discussion. The document is a formal announcement of a transaction in the company's own shares by a shareholder, not a report or regulatory filing. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is short and focused solely on shareholding reduction progress, confirming this classification with high confidence.
2021-05-19 Chinese
关于2018年（第二期）股票期权激励计划预留期权第一个行权期采用自主行权模式的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the exercise of stock options under a specific stock option incentive plan. It details the number of options exercisable, the exercise price, the method of exercise, and the impact on the company's financials. It is not a full financial report, earnings release, or management discussion, but rather a specific update on stock option exercise and related capital changes. This fits best under the category of Capital/Financing Update (CAP), as it relates to financing activities and capital structure changes due to stock option exercises. The document length is short and focused on this specific topic, not a broader report or announcement of a report publication.
2021-05-12 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.